Bevacizumab 400mg/16ml solution for infusion vials
NHS hospitals in England used £66,482,043 of indicative cost of Bevacizumab 400mg/16ml solution for infusion vials in the 12 months to July 2026, about 0.3% of all hospital medicines spend. That is up 30.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Bevacizumab 400mg/16ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Bevacizumab 400mg/16ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Clatterbridge Cancer Centre Nhs Ft | £7,599,623 |
| The Christie Nhs Foundation Trust | £2,514,164 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,906,740 |
| Leeds Teaching Hpls Nhs Trust | £1,906,335 |
| Royal Surrey County Hosp Nhs Found Trust | £1,867,455 |
| United Lincolnshire Hospitals Nhs Trust | £1,799,820 |
| Sheffield Teaching Hospitals Nhs Trust | £1,733,400 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,722,161 |
| The Royal Marsden Nhs Foundation Trust | £1,641,870 |
| East And North Hertfordshire Nhs Trust | £1,564,515 |
The primary-care picture
Bevacizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Bevacizumab medicine page.